Valuation: Prescient Therapeutics Limited

Market Cap 64.14M 44.29M 38.83M 35.79M 33.51M 62.84M 4.18B 430M 166M 2.06B 166M 163M 7.16B P/E 2024
-3.71x
P/E 2025 -4.84x
Enterprise Value 57.22M 39.51M 34.64M 31.93M 29.89M 56.05M 3.73B 384M 148M 1.84B 148M 145M 6.39B EV / Sales 2024
4.42x
EV / Sales 2025 6.54x
Free-Float
89.43%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Prescient Therapeutics Limited

1 day-7.58%
1 week-10.29%
Current month-21.79%
1 month-21.79%
3 months+15.09%
6 months-23.75%
Current year-27.38%
1 week 0.06
Extreme 0.057
0.07
1 month 0.06
Extreme 0.057
0.08
Current year 0.05
Extreme 0.049
0.1
1 year 0.04
Extreme 0.04
0.12
3 years 0.04
Extreme 0.037
0.12
5 years 0.04
Extreme 0.037
0.3
10 years 0.02
Extreme 0.022
0.3
Manager TitleAgeSince
Chief Executive Officer 54 2025-01-19
Director of Finance/CFO 53 -
Chief Tech/Sci/R&D Officer - 2025-03-23
Director TitleAgeSince
Chairman - 2025-03-29
Director/Board Member - 2020-05-31
Director/Board Member 71 2023-05-14
Date Insider Type Main position Quantity % Market Cap.
23-05-01Fiscal year

Chief Executive Officer

1,148,936 0.1430%
23-05-01Expiration

Chief Executive Officer

2,351,064 0.2926%
23-04-03Fiscal year

Chairman

17,813 0.0025%
Change 5-day change 1-year change 3-year change Capi.($)
-7.58%-10.29%+32.61%-22.78% 44.29M
-0.48%+7.20%-5.65%+3.69% 46.2B
+2.19%+11.71%+393.31%+609.31% 38.71B
+2.53%+13.93%+21.38%-10.96% 31.9B
+1.65%+3.61%+16.04%+55.24% 31.12B
-4.16%-2.58%+8.94%+26.14% 23.77B
-0.32%+12.96% - - 16.2B
+1.37%+14.53%+69.64%+136.34% 15.05B
+1.00%+10.30%+13.31%+23.36% 13.74B
+3.63%+9.53%+103.97%+106.25% 13.42B
Average -0.02%+7.19%+72.62%+102.96% 23.02B
Weighted average by Cap. +0.75%+8.71%+88.73%+138.09%

Financials

2024 2025
Net sales 3.71M 2.56M 2.25M 2.07M 1.94M 3.64M 242M 24.9M 9.63M 120M 9.63M 9.41M 414M 4.36M 3.01M 2.64M 2.43M 2.28M 4.27M 284M 29.22M 11.31M 140M 11.29M 11.05M 486M
Net income -8.24M -5.69M -4.99M -4.6M -4.3M -8.07M -537M -55.25M -21.38M -265M -21.36M -20.89M -920M -7.32M -5.06M -4.43M -4.09M -3.83M -7.17M -477M -49.11M -19M -236M -18.99M -18.57M -817M
Net Debt -14.18M -9.79M -8.59M -7.91M -7.41M -13.89M -924M -95.13M -36.81M -457M -36.77M -35.97M -1.58B -6.93M -4.78M -4.19M -3.87M -3.62M -6.79M -451M -46.46M -17.98M -223M -17.96M -17.57M -773M
Logo Prescient Therapeutics Limited
Prescient Therapeutics Limited is a clinical-stage oncology company. It is engaged in developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, CellPryme-M, and OmniCAR. PTX-100 is a first-in-class targeted therapy which can disrupt the RAS family pathway by inhibiting the prenylation action of the enzyme GGT-1. PTX-100 is in a Phase 2a clinical study in refractory/relapsed Cutaneous T Cell Lymphoma with Fast Track Designation. CellPryme-M is a high-performance cell therapy enhancement platform that can improve CAR-T efficacy. The CellPryme platform consists of two distinct components which can be used separately but have significant synergies when used together. OmniCAR is a universal CAR platform that is controllable, with plug and play capabilities to enable a wider range of cancers to be targeted. OmniCAR enables controllable T-cell activity and multiantigen targeting with a single cell product.
Employees
3
Date Price Change Volume
26-06-26 A$0.0610 -7.58% 2,596,939
26-06-25 A$0.0660 +13.79% 1,040,344
26-06-24 A$0.0580 -3.33% 1,489,090
26-06-23 A$0.0600 -7.69% 2,203,233
26-06-22 A$0.0650 -4.41% 398,607